Evidence map›Paper›PMID 41155374›Full record

ArticleInternational journal of molecular sciences2025

Knocking Down FRMD4A, a Factor Associated with the Brain Development Disorder and a Risk Factor for Alzheimer's Disease, Using RNA-Targeting CRISPR/Cas13 Reveals Its Role in Cell Morphogenesis.

Asahi Honjo, Hideji Yako, Yuki Miyamoto, Moeri Yagi, Masahiro Yamamoto, Akinori Nishi, Hiroyuki Sakagami, Junji Yamauchi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Asahi HonjoLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji 192-0982, Tokyo, Japan.
Hideji YakoLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji 192-0982, Tokyo, Japan.ORCID 0000-0003-2632-8488
Yuki MiyamotoLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji 192-0982, Tokyo, Japan.ORCID 0000-0001-9298-5799
Moeri YagiTSUMURA  Advanced Technology Research Laboratories, TSUMURA & CO., Ami, Inashiki 300-1192, Ibaraki, Japan.
Masahiro YamamotoTSUMURA  Advanced Technology Research Laboratories, TSUMURA & CO., Ami, Inashiki 300-1192, Ibaraki, Japan.
Akinori NishiTSUMURA  Advanced Technology Research Laboratories, TSUMURA & CO., Ami, Inashiki 300-1192, Ibaraki, Japan.ORCID 0000-0002-0495-3023
Hiroyuki SakagamiDepartment of Anatomy, Kitasato University School of Medicine, Minami, Sagamihara 252-0374, Kanagawa, Japan.
Junji YamauchiLaboratory of Molecular Neuroscience and Neurology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji 192-0982, Tokyo, Japan.ORCID 0000-0002-3618-998X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic truncation or mutation of the gene encoding band 4.1, ezrin, radixin, and moesin (FERM) domain protein containing 4A (FRMD4A) is associated with brain developmental diseases, including microcephaly with global developmental delay. It has also been identified as a risk factor for Alzheimer's disease. By analogy with other FERM domain-containing proteins, FRMD4A is believed to regulate cell morphogenesis and/or cell polarization in central nervous system (CNS) cells; however, it remains unclear whether and how dysfunction of FRMD4A and/or its closely homologous protein FRMD4B causes abnormal morphogenesis in neuronal cells. Here, we describe for the first time the roles of FRMD4A and FRMD4B in process elongation in neuronal cells. Knockdown of Frmd4a or Frmd4b using specific RNA-targeting clustered regularly interspaced short palindromic repeat (CRISPR) and Cas13-fitted gRNAs led to decreased process elongation in primary cortical neurons. Similar decreases in neuronal marker expression were observed in the N1E-115 cell line, a model of neuronal differentiation. Furthermore, hesperetin, an aglycone of the citrus flavonoid hesperidin known to promote neuroprotective signaling, recovered the decreased process elongation induced by the knockdown of Frmd4a or Frm4b. Hesperetin also stimulated phosphorylation of mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPKs/ERKs), which could help promote neuronal processes. These results suggest that FRMD4A and FRMD4B regulate process elongation through a possible signaling pathway linked to the sustained phosphorylation of MAPKs/ERKs. Crucially, this study reveals that, at the molecular and cellular levels, hesperetin can restore normal phenotypes when FRMD4A protein or FRMD4B protein is impaired.

Indexed as

Alzheimer DiseaseBrainCRISPR-Cas SystemsCytoskeletal ProteinsMembrane ProteinsMorphogenesisAnimalsCell LineGene Knockdown TechniquesHumansMiceNeuronsCytoskeletal ProteinsMembrane ProteinsFRMD4AFRMD4Bhesperetinmorphogenesisneuronal cell

Identifiers

PMID41155374
PMCPMC12563601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.